- Home
- CSTL vs MUA Comparison
CSTL vs MUA Comparison
Compare CSTL & MUA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- MUA
- Stock Information
- Founded
- CSTL 2007
- MUA 1993
- Country
- CSTL United States
- MUA United States
- Employees
- CSTL N/A
- MUA N/A
- Industry
- CSTL Medical Specialities
- MUA Investment Bankers/Brokers/Service
- Sector
- CSTL Health Care
- MUA Finance
- Exchange
- CSTL Nasdaq
- MUA Nasdaq
- Market Cap
- CSTL 471.5M
- MUA 405.2M
- IPO Year
- CSTL 2019
- MUA N/A
- Fundamental
- Price
- CSTL $19.36
- MUA $10.45
- Analyst Decision
- CSTL Strong Buy
- MUA
- Analyst Count
- CSTL 6
- MUA 0
- Target Price
- CSTL $37.67
- MUA N/A
- AVG Volume (30 Days)
- CSTL 554.7K
- MUA 92.6K
- Earning Date
- CSTL 08-04-2025
- MUA 01-01-0001
- Dividend Yield
- CSTL N/A
- MUA 4.84%
- EPS Growth
- CSTL N/A
- MUA N/A
- EPS
- CSTL N/A
- MUA N/A
- Revenue
- CSTL $346,269,000.00
- MUA N/A
- Revenue This Year
- CSTL N/A
- MUA N/A
- Revenue Next Year
- CSTL $1.62
- MUA N/A
- P/E Ratio
- CSTL N/A
- MUA N/A
- Revenue Growth
- CSTL 20.40
- MUA N/A
- 52 Week Low
- CSTL $14.59
- MUA $8.61
- 52 Week High
- CSTL $35.84
- MUA $11.43
- Technical
- Relative Strength Index (RSI)
- CSTL 58.66
- MUA 64.22
- Support Level
- CSTL $18.81
- MUA $10.02
- Resistance Level
- CSTL $21.33
- MUA $10.41
- Average True Range (ATR)
- CSTL 0.92
- MUA 0.12
- MACD
- CSTL 0.45
- MUA 0.02
- Stochastic Oscillator
- CSTL 70.74
- MUA 81.13
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.